Business Context and Reporting Period
Company: Inmune Bio, Inc. (Nasdaq: INMB)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Inmune Bio is a clinical-stage biotechnology company developing immunotherapies targeting innate immune dysfunction. The company focuses on three primary platforms: XPro1595 (DN-TNF) for Alzheimer's Disease (AD) and Treatment Resistant Depression (TRD); INKmune (NK cell priming) for cancer; and CORDStrom (mesenchymal stem cells) for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $14 | $155 |
| Net Loss | $(42,082) | $(30,008) |
| Research & Development Expenses | $33,166 | $20,273 |
| General & Administrative Expenses | $9,483 | $9,623 |
| Cash and Cash Equivalents (Year End) | $20,922 | $35,848 |
| Accumulated Deficit | $(163,104) | $(121,022) |
| Net Cash Used in Operating Activities | $(33,361) | $(11,980) |
| Net Cash Provided by Financing Activities | $18,211 | $(4,225) |
Note: The company reported no debt as of December 31, 2024, having paid off its term loan in full during the year.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $12.1 million (40%) to $42.1 million, driven primarily by a $12.9 million increase in R&D expenses.
- R&D Spend Surge: R&D expenses rose 64% year-over-year. This was due to $9.9 million in higher costs for the Alzheimer's clinical trial, $1.3 million for INKmune/CORDStrom trials, and reduced R&D tax rebates.
- Revenue Decline: Revenue dropped to $14,000 from $155,000, reflecting minimal sales of mesenchymal stromal cells to a single UK customer.
- Debt Elimination: The company repaid $10 million of principal on its term loan in 2024, resulting in zero debt on the balance sheet and a reduction in interest expense.
- Financing Activity: The company raised approximately $27.8 million in net proceeds from equity sales (ATM and registered direct offerings) in 2024, compared to minimal equity raises in 2023.
Guidance, Outlook, and Risks
Clinical and Regulatory Outlook
- CORDStrom (RDEB): Completed a pivotal blinded randomized cross-over trial. Data indicates significant reduction in itch and pain. The company plans to file a Biologics License Application (BLA) with the FDA in late 2025 or early 2026. Received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD).
- XPro1595 (Alzheimer's): Phase II trial (AD02) enrollment completed in November 2024 with 208 patients. Top-line cognitive data (EMACC) expected in June 2025. A Phase II trial for Treatment Resistant Depression (TRD) is expected to start enrollment in 2025.
- INKmune (Cancer): Phase I/II trial in metastatic castrate-resistant prostate cancer (mCRPC) is ongoing. Enrollment expected to complete in H1 2025 with data lock in H2 2025.
- Capital Requirements: Failure to raise additional capital could force the company to delay, scale back, or discontinue product development.
- Clinical Trial Outcomes: High risk of failure in clinical trials; interim data may not predict final results.
- Regulatory Approval: No assurance that products will receive FDA or EMA approval.
- Competition: Intense competition from larger biopharmaceutical companies with greater resources.
- Cash Runway: Verify the sufficiency of the $20.9 million cash balance against projected burn rates for 2025 clinical trials.
- Financing Plans: Monitor upcoming equity offerings (ATM program and registered direct offerings) for dilution impact.
- CORDStrom BLA Timeline: Confirm the company's ability to meet the late 2025/early 2026 BLA submission target.
- XPro Phase II Data: Await the June 2025 top-line data release for the Alzheimer's trial to assess commercial viability.
- Vendor Dispute: Review the status of the $1.4 million disputed vendor invoice noted in the commitments and contingencies section.
Liquidity and Going Concern
The company has incurred significant losses and negative cash flows since inception. As of December 31, 2024, cash balances of $20.9 million are projected to be insufficient to sustain operations for one year following the issuance of financial statements. The independent auditor has issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management plans to secure additional funding through equity sales, debt financing, or collaborations.